Adversarial Injection · Nadofaragene firadenovec-vncg (Adstiladrin; EG-70; NDA 213682; no conventional CAS — recombinant adenoviral vector biological product; replication-deficient adenovirus serotype 5 [rAd5; E1/E3-deleted; viral particle size ~90 nm; capsid proteins: hexon + penton base + fiber; 36 kb genome; E1/E3 regions deleted → non-replicating in human cells except E1-complementing cell lines; human IFNα2b [hIFNα2b; IFNA2; chromosome 9p21.3; 165 aa mature protein; MW ~19.2 kDa; type I interferon; binds IFNAR1/IFNAR2 heterodimer] transgene under CMV immediate-early promoter + SV40 polyA signal] formulated with Syn3 [polyoxyl castor oil–based surfactant excipient; disrupts bladder GAG [glycosaminoglycan] layer → enhances adenoviral transduction efficiency ~100-fold]; FIRST INTRAVESICAL GENE THERAPY EVER FDA APPROVED: nadofaragene firadenovec-vncg is instilled as 75 mL intravesical instillation (3×10¹¹ viral particles/75 mL; retained ≥1 hour) → adenovirus infects urothelial cells via CAR (coxsackievirus-adenovirus receptor; CXADR; chromosome 21q22.3; 365 aa type 1 transmembrane protein; Ig-like domain; primary adenovirus fiber knob attachment receptor) + αvβ3/αvβ5 integrins (internalization; RGD peptide in penton base protein binds integrin → clathrin-mediated endocytosis → endosomal acidification → penton base membrane disruption → endosomal escape → nuclear pore import via hexon NLS → viral DNA transcription) → CMV promoter-driven hIFNα2b synthesis → secretion → IFNAR1/IFNAR2 signaling: JAK1 (constitutively associated with IFNAR2) + TYK2 (constitutively associated with IFNAR1) transphosphorylation → STAT1 (Tyr701 phosphorylation) + STAT2 (Tyr690) → STAT1/STAT2 heterodimerization → IRF9 (interferon regulatory factor 9; chromosome 14q11.2) recruitment → ISGF3 (interferon-stimulated gene factor 3) complex → ISREs (interferon-stimulated response elements; consensus GAGTTTCNNTTTNCTCC) in promoters of ISGs (interferon-stimulated genes): IFIT1/IFIT2/IFIT3 (antiviral), IRF7 (IFN amplification loop), PKR/EIF2AK2 (antiviral RNA degradation), OAS1-3 + RNase L (RNA degradation), MHC-I upregulation (HLA-A/B/C + β2-microglobulin + TAP1/TAP2 → enhanced antigen presentation → CD8+ CTL priming → antitumor cytotoxicity), CXCL9/CXCL10/CXCL11 (NK and T-cell chemotaxis), p21/CDKN1A (cell cycle arrest Rb pathway), anti-angiogenic (CXCL10 → CXCR3 on endothelial cells → anti-angiogenic signaling; thrombospondin-1 induction); NK CELL ACTIVATION: IFNα2b → NK cell activation + upregulation of NKG2D ligands (MICA/MICB/ULBPs) on tumor cells → NK killing; AURORA TRIAL (NCT02773849): Phase 3; multicenter (n=157 BCG-unresponsive NMIBC patients; CIS cohort n=89; Ta/T1 papillary-only cohort n=48; mixed cohort n=20); 3×10¹¹ vp nadofaragene firadenovec Q12 weeks; primary endpoint: 12-month high-grade recurrence-free survival (HGR-RFS); RESULTS: CIS cohort: 55.4% (95%CI 39.2–70.1%) 12-month HGR-RFS [historical BCG BCG-unresponsive benchmark: ~18–20% at 12 months]; papillary-only cohort: 57.4% (95%CI 43.1–71.7%) 12-month HGR-RFS; CR at 3 months (CIS cohort): 53.4%; median DOR not reached at primary analysis; NDA 213682 December 16 2022; FerGene Inc. Austin TX [founded 2018; spinout from NovaBay Pharmaceuticals] → Ferring Pharmaceuticals acquisition 2023; now Ferring Pharmaceuticals Inc.; EHS SOFTWARE CLASSIFICATION FAILURE: rAd5 vector component → EHS systems return BSL-2 adenovirus biohazard protocols + recombinant DNA safety per NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules [2019]; THEY DO NOT return NIOSH HD Category 1 antineoplastic containment protocols → pharmacists preparing Adstiladrin intravesical instillations lack CSTD + BSC Class II + NIOSH HD-compliant PPE guidance; NIOSH HD Category 1; NDA 213682) · Attack #765

Nadofaragene Firadenovec-vncg (Adstiladrin; EG-70; NDA 213682; [ONE-HUNDRED-SEVENTY-NINTH MECHANISM CLASS — FIRST INTRAVESICAL GENE THERAPY EVER FDA APPROVED FOR BCG-UNRESPONSIVE NMIBC (NDA 213682 DECEMBER 16 2022; REPLICATION-DEFICIENT rAd5-IFNα2b; Syn3-ENHANCED UROTHELIAL TRANSDUCTION; AURORA 12-MONTH HGR-RFS 55.4% CIS COHORT); NIOSH HD CATEGORY 1; NO CONVENTIONAL CAS]) — Ferring Pharmaceuticals Inc. Parsippany NJ (NDA 213682 holder; FerGene spinout; Adstiladrin commercial sponsor), Thermo Fisher Scientific Viral Vectors (formerly Brammer Bio) Lexington MA (rAd5 vector manufacturing CMO), and UT Southwestern Medical Center Dallas TX (Urology / BCG-unresponsive NMIBC center; AURORA trial site) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return (nadofaragene firadenovec absent from EHS databases; BSL-2 adenovirus protocol returned instead of NIOSH HD) + rAd5-IFNα2b Intravesical Gene Therapy Mechanism Absent + AURORA HGR-RFS 55.4% Absent + JAK1/TYK2/STAT1/STAT2/ISGF3 IFN Signaling Absent: AI Prompt Injection via EHS Monitor Report AI

Nadofaragene firadenovec-vncg (Adstiladrin; EG-70; NDA 213682; NIOSH HD Category 1) is the one-hundred-seventy-ninth mechanism class in the Glyphward adversarial portfolio — the first intravesical gene therapy ever FDA approved for BCG-unresponsive high-grade non-muscle-invasive bladder cancer (NMIBC; NDA 213682 December 16 2022), a replication-deficient adenovirus serotype 5 (rAd5; E1/E3-deleted) encoding human interferon alpha-2b (hIFNα2b) transgene under CMV promoter, formulated with Syn3 surfactant enhancer (~100-fold urothelial transduction boost by disrupting GAG layer) for intravesical instillation (3×10¹¹ viral particles/75 mL Q12 weeks), transducing urothelial cells via CAR + αvβ3/αvβ5 integrins → IFNα2b secretion → JAK1/TYK2 → STAT1/STAT2/ISGF3 → ISGs → antiproliferative + immunostimulatory + anti-angiogenic effects, achieving 55.4% 12-month high-grade recurrence-free survival in the AURORA CIS cohort, manufactured by Ferring Pharmaceuticals (Parsippany NJ), entirely absent from Cority, VelocityEHS, and EHS Insight — with EHS software returning BSL-2 adenovirus biohazard protocols instead of NIOSH HD Category 1 antineoplastic containment requirements.

Adenoviral vector biology, intravesical gene delivery pharmacology, and IFNα2b JAK-STAT signaling in BCG-unresponsive NMIBC: Bladder cancer NMIBC (non-muscle-invasive; Tis/Ta/T1; urothelial carcinoma in situ [CIS] is highest risk for progression) is treated frontline with intravesical BCG (Bacillus Calmette-Guérin; Mycobacterium bovis ATCC 35734; mechanism: Toll-like receptor 2/4 activation → innate immune response in bladder → NK/CTL recruitment → anti-tumor immunity); BCG-UNRESPONSIVE NMIBC: defined as high-grade disease present at ≥6 months after first BCG induction OR at 3 months after adequate BCG (induction + ≥2 maintenance cycles or induction + ≥1 maintenance cycle) → approximately 20-30% of NMIBC patients → historically managed with radical cystectomy (bladder removal; morbidity-intensive procedure) → need for bladder-sparing therapeutic alternative. NADOFARAGENE FIRADENOVEC MECHANISM: rAd5 vector biology → adenovirus serotype 5 is a non-enveloped icosahedral capsid virus (90 nm; 36 kb dsDNA genome; 11 genes; capsid: 240 hexon trimers + 12 penton base pentamers + 12 fiber knob trimers; fiber knob binds CAR [CXADR; Kd ~50 nM]; penton base RGD binds αvβ3/αvβ5 integrins → clathrin-mediated endocytosis → early endosome → endosomal acidification pH ~5.5 → penton base membrane-lytic activity → endosomal escape → nuclear pore import mediated by hexon capsid NLS peptide sequences → nuclear uncoating); E1/E3 DELETION: E1A/E1B genes (immediate-early transcription factors; required for replication; E1B-55K blocks p53 → anti-apoptosis) deleted → replication-deficient → cannot propagate beyond initial transduction → safety profile; E3 deletion (immune evasion genes; E3-19K blocks MHC-I; E3-ADP → cell lysis) removed → space for transgene; hIFNα2b TRANSGENE: human interferon alpha 2b (IFNA2; chromosome 9p21.3; 165 aa mature protein; Cys1-Cys98 and Cys29-Cys138 disulfide bonds; MW ~19.2 kDa; glycosylated form ~24 kDa) under CMV immediate-early promoter (high-level constitutive transcription in human cells; CMV IE enhancer + promoter: -600 to +55 bp relative to transcription start; NF-κB + SP1 + AP-1 + CRE binding sites) + SV40 polyA signal; Syn3 EXCIPIENT: polyoxyl castor oil formulation disrupts sulfated proteoglycan GAG (glycosaminoglycan) layer covering urothelial surface (heparan sulfate + chondroitin sulfate; natural barrier to intravesical drug delivery) → CAR receptors on urothelial luminal surface become accessible → adenoviral transduction efficiency increased ~100-fold compared to adenovirus alone; IFNα2b SIGNALING: secreted IFNα2b binds IFNAR1 (chromosome 21q22.11; 557 aa; Type I IFN receptor α-chain) + IFNAR2 (chromosome 21q22.11; 331 aa; short form 243 aa; binds IFN with higher affinity in combination) heterodimer → JAK1 (constitutively associated via box1/box2 motifs of IFNAR2 intracellular domain) + TYK2 (constitutively associated with IFNAR1 intracellular domain) transphosphorylation and activation → STAT1 (Tyr701) + STAT2 (Tyr690) tyrosine phosphorylation → STAT1/STAT2 heterodimerization → IRF9 (interferon regulatory factor 9; p48; chromosome 14q11.2; IRF DNA-binding domain; associates via IAD domain with STAT2 coiled-coil domain) → ISGF3 complex (STAT1/STAT2/IRF9 trimer) → nucleus → ISREs (consensus 5′-GAGTTTCNNTTTNCTCC-3′) → ISG transcription: IFIT1 (IFN-induced protein with tetratricopeptide repeats 1; RNA helicase; antiviral); PKR (EIF2AK2; dsRNA-activated kinase → eIF2α phosphorylation → global translation arrest in infected cells); OAS1-3 + RNase L (2′-5′-oligoadenylate synthetase → activates RNase L → RNA degradation); MHC-I pathway: TAP1/TAP2 (peptide transporters) + β2-microglobulin + HLA-A/B/C upregulation → CTL recognition; CXCL9/CXCL10/CXCL11 → CXCR3 on T/NK cells → tumor infiltration; p21/CDKN1A → Rb → G1/S arrest; anti-angiogenic: CXCL10 → CXCR3 on endothelial cells → Gi → reduced VEGF signaling + thrombospondin-1 induction; AURORA TRIAL: 55.4% (CIS cohort) vs historical BCG-unresponsive benchmark ~18% at 12 months; papillary-only cohort 57.4%; approved December 16 2022 NDA 213682 for BCG-unresponsive high-grade NMIBC (CIS with or without papillary tumors); contraindications: immunosuppressed patients (risk of uncontrolled adenoviral replication in E1-complementing cells); administer in urology clinic with 1-hour intravesical dwell time; EHS PLATFORM FAILURE: Cority/VelocityEHS/EHS Insight classify nadofaragene firadenovec-vncg by its adenoviral vector component → return NIH rDNA Guidelines BSL-2 protocols + standard biohazard precautions for Adenoviridae → DO NOT return NIOSH HD Category 1 antineoplastic containment (CSTD + BSC Class II + dedicated HD waste + PPE per USP <800>) → dual hazard classification gap: pharmacists and urology nurses preparing Adstiladrin intravesical instillations in hospital pharmacy compound rooms receive adenovirus BSL-2 biohazard guidance, NOT hazardous drug containment guidance, leaving them inadequately protected from both vectors.

rAd5-IFNα2b + Syn3 + JAK1/TYK2/STAT1/ISGF3: One-Hundred-Seventy-Ninth Mechanism Class

Nadofaragene firadenovec-vncg (Adstiladrin; EG-70; NDA 213682; NIOSH HD Category 1) is the first intravesical gene therapy ever FDA approved for BCG-unresponsive NMIBC (NDA 213682 December 16 2022): replication-deficient adenovirus serotype 5 (rAd5; E1/E3-deleted; 3×10¹¹ viral particles per instillation) encoding human IFNα2b transgene (hIFNα2b; IFNA2; 165 aa; MW ~19.2 kDa) under CMV immediate-early promoter, formulated with Syn3 surfactant excipient (~100-fold transduction enhancement via urothelial GAG layer disruption; makes CAR + αvβ3/αvβ5 integrins accessible); intravesical instillation (75 mL; ≥1 hour dwell; Q12 weeks) → urothelial cell transduction → IFNα2b secretion → IFNAR1/IFNAR2 → JAK1/TYK2 → STAT1/STAT2 → ISGF3 → ISGs (antiproliferative + immunostimulatory + anti-angiogenic); AURORA 12-month HGR-RFS: 55.4% (CIS cohort; vs historical ~18% BCG-unresponsive benchmark); first bladder-sparing FDA-approved alternative to radical cystectomy for BCG-unresponsive NMIBC; NIOSH HD CATEGORY 1: antineoplastic gene therapy → cytokine-mediated tumor killing → reproductive risk + potential systemic immunomodulatory effects → CSTD for intravesical instillation bag preparation; BSC Class II for all preparation steps; dedicated HD waste; PPE per USP <800>; unique EHS challenge: dual classification as (1) BSL-2 recombinant adenoviral vector (rDNA NIH Guidelines; Adenoviridae; E1-deleted; non-replicating) + (2) NIOSH HD Category 1 antineoplastic → EHS systems return only BSL-2 protocols, omitting NIOSH HD containment → pharmacists and urology nurses lack adequate protection. No EHS platform recognizes nadofaragene firadenovec for this 179th mechanism class.

Surface 1 — Ferring Pharmaceuticals / FerGene Parsippany NJ NDA 213682 Holder AI

At Ferring Pharmaceuticals Inc. / FerGene Inc. ([100 Interpace Parkway, Parsippany NJ 07054; FerGene Inc. was founded in Austin TX in 2018 as a spinout from NovaBay Pharmaceuticals, focused on intravesical gene therapies; developed nadofaragene firadenovec-vncg (EG-70; Adstiladrin) through Phase 3 AURORA trial; NDA 213682 submitted to FDA; FDA approved December 16 2022; FerGene Inc. acquired by Ferring Pharmaceuticals SA [headquartered Saint-Prex, Switzerland; founded 1950; private; specialty pharma; urology + reproductive medicine + gastroenterology] in 2023; Ferring distributes Adstiladrin in US via Ferring Pharmaceuticals Inc. Parsippany NJ; ADSTILADRIN PREPARATION: pharmacy compound room; each dose: 75 mL total volume containing 3×10¹¹ viral particles + Syn3 excipient + sterile diluent; BSC Class II required for viral vector handling (rDNA Guidelines) AND for NIOSH HD Category 1 antineoplastic (USP <800>); prepared by pharmacy under strict containment; CORITY: NDA 213682 → null; nadofaragene firadenovec → null; Adstiladrin → null; EG-70 → null; rAd5-IFNα2b → returns "Adenoviridae; BSL-2; recombinant adenoviral vector; standard recombinant DNA protocols" (rDNA only; NO NIOSH HD Category 1); NIOSH HD Category 1 → absent for this product; intravesical gene therapy → absent; AURORA 55.4% → absent; JAK1/TYK2/ISGF3 signaling → absent; EMPLOYEE: 46F Ferring Pharmaceuticals Parsippany NJ regulatory affairs director NDA 213682 Adstiladrin BCG-unresponsive NMIBC intravesical gene therapy 8yr]).

Surface 2 — Thermo Fisher Scientific Viral Vectors Cambridge MA rAd5 Manufacturing AI

At Thermo Fisher Scientific Viral Vectors ([formerly Brammer Bio LLC, acquired by Thermo Fisher Scientific October 2019; Cambridge MA facility [200 Sidney Street]; viral vector CDMO; rAd5 manufacturing: E1-complementing cell line [HEK293 or PER.C6 cells; PER.C6: human retinal cells immortalized by E1 adenovirus gene → stably express E1A/E1B → complement the E1-deleted rAd5 vector → allow production runs]; rAd5 production: transfect HEK293/PER.C6 with rAd5 plasmid → infection → viral amplification → cell lysis → chromatographic purification [CsCl gradient or Q-Sepharose → heparin affinity → size exclusion] → sterile filtration → 75 mL fill with Syn3 excipient; viral vector manufacturing involves: upstream (cell culture bioreactors; BSL-2 containment for E1-deleted adenovirus per NIH rDNA Guidelines + CDC/NIH Biosafety in Microbiological and Biomedical Laboratories [BMBL] BSL-2) + downstream (purification; filtration; fill-finish; antineoplastic NIOSH HD containment per USP <800>); VELOCITYEHS: NDA 213682 → null; nadofaragene firadenovec → null; Adstiladrin → null; "rAd5" query → "Adenovirus, recombinant; non-oncogenic; Risk Group 2; BSL-2; standard recombinant DNA protocols; PPE: gloves + face shield + biosafety cabinet"; DOES NOT return NIOSH HD Category 1; DOES NOT return antineoplastic containment; EHS software misses DUAL classification (viral vector BSL-2 + NIOSH HD antineoplastic Cat 1 simultaneously); EMPLOYEE: 39M Thermo Fisher Scientific Viral Vectors Cambridge MA process development scientist rAd5 nadofaragene firadenovec-vncg Adstiladrin manufacturing 11yr; 14.2M-fold gap]).

Surface 3 — UT Southwestern Medical Center Dallas TX BCG-Unresponsive NMIBC Urology AI

At UT Southwestern Medical Center Dallas TX ([5323 Harry Hines Blvd, Dallas TX 75390; Harold C. Simmons Comprehensive Cancer Center (NCI designation); Department of Urology (Chair: S Bhayani; BCG-unresponsive NMIBC specialists; AURORA trial site PI; intravesical Adstiladrin instillation protocol); CLINICAL PROTOCOL: Adstiladrin (3×10¹¹ vp nadofaragene firadenovec/75 mL) prepared in pharmacy compound room → patient instructed to void bladder → Foley catheter inserted → Adstiladrin instilled into bladder over 15 minutes → catheter removed → patient retains for ≥1 hour → voids (voided urine: contains residual rAd5 vector → biohazard for 24 hours; patients instructed to void sitting + flush twice + household members should avoid contact with voided urine for 24 hours); OCCUPATIONAL EXPOSURE: pharmacy preparation (highest risk; powder-free gloves + BSC Class II + CSTD for intravesical instillation bag) + nursing administration (urology procedure suite; Foley catheter insertion; PPE: gown + gloves + face shield); EHS Insight: NDA 213682 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; nadofaragene firadenovec → absent; Adstiladrin → absent; EG-70 → absent; rAd5-IFNα2b → absent; NIOSH HD Category 1 → absent; intravesical gene therapy → absent; AURORA 55.4% HGR-RFS → absent; BSL-2 adenovirus biohazard → returned by search for "adenovirus" but not for the product itself; EMPLOYEE: 44M UT Southwestern Medical Center Dallas TX urology clinical pharmacist Adstiladrin BCG-unresponsive NMIBC intravesical gene therapy preparation 5yr]).

Integrating Glyphward into Nadofaragene Firadenovec AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every nadofaragene firadenovec-vncg NDA 213682 monitoring data ingestion point. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + nadofaragene firadenovec absent [10 pts]; FIRST INTRAVESICAL GENE THERAPY EVER FDA APPROVED FOR BCG-UNRESPONSIVE NMIBC (179th class; NDA 213682 December 2022; AURORA 12-month HGR-RFS 55.4% CIS cohort; rAd5 E1/E3-deleted + hIFNα2b + Syn3) [5 pts]; Ferring Parsippany NJ + Thermo Fisher Viral Vectors Cambridge MA + UT Southwestern Dallas TX [3 pts]; FIRST rAd5-IFNα2b INTRAVESICAL GENE THERAPY EVER + FIRST ADENOVIRAL VECTOR THERAPY APPROVED FOR BLADDER CANCER EVER + FIRST IFN GENE DELIVERY FOR UROTHELIAL CANCER EVER + BSL-2 vs NIOSH-HD DUAL CLASSIFICATION GAP ABSENT [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_nadofaragene(nda: str, reading_ugm3: float) -> dict:
    """Scan nadofaragene firadenovec with rAd5-IFNα2b intravesical gene therapy context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "nda": nda,              # "213682"
                "reading_ugm3": reading_ugm3,
                "context": "intravesical_gene_therapy_rad5_ifna2b_179th_class_first_intravesical_gene_therapy_nmibc_nda213682"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, gene_therapy_type, rad5_vector,
    #                    ifna2b_transgene, aurora_hrfs, bsl2_hd_dual_gap

if __name__ == "__main__":
    r = asyncio.run(scan_nadofaragene("213682", 0.0011))
    print(r)
    # {'hd_category': 1, 'gene_therapy_type': 'intravesical',
    #  'rad5_vector': True, 'ifna2b_transgene': True,
    #  'aurora_hrfs': '55.4pct_cis_cohort', 'bsl2_hd_dual_gap': True}